Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

398 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain.
Simpson K, Leyendecker P, Hopp M, Müller-Lissner S, Löwenstein O, De Andrés J, Troy Ferrarons J, Bosse B, Krain B, Nichols T, Kremers W, Reimer K. Simpson K, et al. Among authors: kremers w. Curr Med Res Opin. 2008 Dec;24(12):3503-12. doi: 10.1185/03007990802584454. Curr Med Res Opin. 2008. PMID: 19032132 Clinical Trial.
Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial.
Löwenstein O, Leyendecker P, Hopp M, Schutter U, Rogers PD, Uhl R, Bond S, Kremers W, Nichols T, Krain B, Reimer K. Löwenstein O, et al. Among authors: kremers w. Expert Opin Pharmacother. 2009 Mar;10(4):531-43. doi: 10.1517/14656560902796798. Expert Opin Pharmacother. 2009. PMID: 19243306 Clinical Trial.
Long-term efficacy and safety of oxycodone-naloxone prolonged-release formulation (up to 180/90 mg daily) - results of the open-label extension phase of a phase III multicenter, multiple-dose, randomized, controlled study.
Dupoiron D, Stachowiak A, Loewenstein O, Ellery A, Kremers W, Bosse B, Hopp M. Dupoiron D, et al. Among authors: kremers w. Eur J Pain. 2017 Oct;21(9):1485-1494. doi: 10.1002/ejp.1050. Epub 2017 May 4. Eur J Pain. 2017. PMID: 28474460 Free PMC article. Clinical Trial.
Pansomatostatin Agonist Pasireotide Long-Acting Release for Patients with Autosomal Dominant Polycystic Kidney or Liver Disease with Severe Liver Involvement: A Randomized Clinical Trial.
Hogan MC, Chamberlin JA, Vaughan LE, Waits AL, Banks C, Leistikow K, Oftsie T, Madsen C, Edwards M, Glockner J, Kremers WK, Harris PC, LaRusso NF, Torres VE, Masyuk TV. Hogan MC, et al. Clin J Am Soc Nephrol. 2020 Sep 7;15(9):1267-1278. doi: 10.2215/CJN.13661119. Epub 2020 Aug 25. Clin J Am Soc Nephrol. 2020. PMID: 32843370 Free PMC article. Clinical Trial.
Bacterial Cholangitis in Autosomal Dominant Polycystic Kidney and Liver Disease.
Martin WP, Vaughan LE, Yoshida K, Takahashi N, Edwards ME, Metzger A, Senum SR, Masyuk TV, LaRusso NF, Griffin MD, El-Zoghby Z, Harris PC, Kremers WK, Nagorney DM, Kamath PS, Torres VE, Hogan MC. Martin WP, et al. Mayo Clin Proc Innov Qual Outcomes. 2019 May 27;3(2):149-159. doi: 10.1016/j.mayocpiqo.2019.03.004. eCollection 2019 Jun. Mayo Clin Proc Innov Qual Outcomes. 2019. PMID: 31193902 Free PMC article.
398 results